Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of BIIB074 Versus Placebo in the Treatment of Primary Inherited Erythromelalgia

Next Previous
X
Search
Trial Profile

An Exploratory, Randomized, Double-Blind, Crossover Study to Compare the Efficacy and Safety of BIIB074 Versus Placebo in the Treatment of Primary Inherited Erythromelalgia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Apr 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vixotrigine (Primary)
  • Indications Erythromelalgia
  • Focus Therapeutic Use
  • Sponsors Convergence Pharmaceuticals

    • Most Recent Events

    • 29 Mar 2021 Results of Population PK model analysis from 12 clinical studies: SCB107718, SCB107727, SCB113210, SCB113210, 802HV101, 802HV102, 802HV104, 802HV105, 802HV106, 802HV107, 1014802/202, 1014802/201 and 1014802/205 published in the European Journal of Drug Metabolism and Pharmacokinetics
    • 24 Jan 2017 Status changed from active, no longer recruiting to completed.
    • 07 Nov 2016 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top